Beyond Air Reports Interim Data Of Self-Administered Inhaled NO For Lung Disease

Beyond Air Inc XAIR has announced interim data from Australia's ongoing LungFit GO pilot study.
Related: Beyond Air Issues Regulatory Update For LungFit PH System.
In this study, patients self-administered high concentration inhaled nitric oxide (NO) at home to treat severe nontuberculous mycobacterial (NTM) lung disease.
The Company expects complete safety and efficacy results to be reported in 2022.
At the data cutoff on September 6, 8 subjects were enrolled in the pilot study.
Interim data showed that high concentration inhaled NO was well tolerated with no study discontinuations and no treatment-related serious adverse events.
All eight subjects were successfully titrated to 250 ppm NO in the hospital setting, and none have required dose reductions during the subsequent at-home portion of the study.
Methemoglobin and NO2 concentrations remained within acceptable ranges in all subjects and below the safety thresholds of 10% and 5 ppm, respectively.
Price Action: XAIR shares up 5.30% at $10.22 during the market session on the last check Wednesday.